|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/08 | |
| A61K 39/39 | |||
| A61K 39/395 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2608799 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11820530.1 |
| Europos patento paraiškos padavimo data | 2011-08-23 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-07-03 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-12-12 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/048823 |
| Data | 2011-08-23 |
| (87) | Numeris | WO 2012/027379 |
| Data | 2012-03-01 |
| (30) | Numeris | Data | Šalis |
| 376582 P | 2010-08-24 | US |
| (72) |
OKADA, Hideho, US
|
| (73) |
University of Pittsburgh - Of the Commonwealth System of Higher Education,
200 Gardner Steel Conference Center, Pittsburgh, PA 15260,
US
|
| (54) | INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES |
| INTERLEUKIN-13 RECEPTOR ALPHA 2 PEPTIDE-BASED BRAIN CANCER VACCINES |